Alpine Immune Sciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, autoimmune/inflammatory disorders, and other diseases. Its product pipeline includes ALPN-101, an inducible T cell costimulator (ICOS)/cluster of differentiation 28 (CD28) antagonist program for the treatment of autoimmune and inflammatory diseases; ALPN-202, a conditional CD28 costimulator and dual checkpoint inhibitor for the treatment of cancer; and ALPN-303, a dual B cell cytokine antagonist for the treatment of B cell-mediated inflammatory and autoimmune diseases. The company has a collaboration agreement with AbbVie Ireland Unlimited Company for the development of ALPN-101; and Adaptimmune Therapeutics plc to develop next-generation SPEAR T cell products. Alpine Immune Sciences, Inc. was incorporated in 2007 and is headquartered in Seattle, Washington.
P/S ratio for Alpine Immune Sciences, Inc. (ALPN)
P/S ratio as of 2023: 16.19
According to Alpine Immune Sciences, Inc.'s latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 16.19. At the end of 2022 the company had a P/S ratio of 8.17.
P/S ratio history for Alpine Immune Sciences, Inc. from 2012 to 2023
P/S ratio at the end of each year
| Year | P/S ratio |
|---|---|
| 2023 | 16.19 |
| 2022 | 8.17 |
| 2021 | 15.05 |
| 2020 | 28.11 |
| 2019 | 40.52 |
| 2018 | 72.29 |
| 2017 | 41.94 |
| 2016 | 11.76 |
| 2015 | 147.42 |
| 2014 | 0.00 |
| 2013 | 0.00 |
| 2012 | 0.00 |